( January 3, 2025, 10:13 AM EST) -- WASHINGTON, D.C. — A federal judge in Delaware did not err in ruling that claims in a series of patents owned by Purdue Pharma LP and related entities directed at changes to the formulation of the company’s Oxycontin drug were invalid, a Federal Circuit U.S. Court of Appeals panel held....